Head to Head Survey: Cellectar Biosciences (NASDAQ:CLRB) versus Its Competitors

Cellectar Biosciences (NASDAQ: CLRB) is one of 113 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Cellectar Biosciences to related companies based on the strength of its profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Cellectar Biosciences and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Cellectar Biosciences N/A -$6.18 million -1.43
Cellectar Biosciences Competitors $8.39 billion $1.12 billion 130.15

Cellectar Biosciences’ rivals have higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

2.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 42.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 10.2% of Cellectar Biosciences shares are held by insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares Cellectar Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectar Biosciences N/A -97.67% -84.22%
Cellectar Biosciences Competitors -2,487.13% -62.29% -9.29%

Analyst Ratings

This is a summary of current recommendations for Cellectar Biosciences and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences 0 0 2 0 3.00
Cellectar Biosciences Competitors 843 3729 6694 185 2.54

Cellectar Biosciences currently has a consensus price target of $2.70, suggesting a potential upside of 76.47%. As a group, “Pharmaceuticals” companies have a potential upside of 25.81%. Given Cellectar Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than its rivals.

Volatility and Risk

Cellectar Biosciences has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Cellectar Biosciences’ rivals have a beta of 33.35, indicating that their average share price is 3,235% more volatile than the S&P 500.


Cellectar Biosciences rivals beat Cellectar Biosciences on 8 of the 12 factors compared.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply